JP2017506626A5 - - Google Patents

Download PDF

Info

Publication number
JP2017506626A5
JP2017506626A5 JP2016550471A JP2016550471A JP2017506626A5 JP 2017506626 A5 JP2017506626 A5 JP 2017506626A5 JP 2016550471 A JP2016550471 A JP 2016550471A JP 2016550471 A JP2016550471 A JP 2016550471A JP 2017506626 A5 JP2017506626 A5 JP 2017506626A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
antibody
antigen
binding fragment
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016550471A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017506626A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/015633 external-priority patent/WO2015123423A2/en
Publication of JP2017506626A publication Critical patent/JP2017506626A/ja
Publication of JP2017506626A5 publication Critical patent/JP2017506626A5/ja
Pending legal-status Critical Current

Links

JP2016550471A 2014-02-14 2015-02-12 中程度用量スタチン療法により適切に管理されない高コレステロール血症を有する患者を処置するための方法 Pending JP2017506626A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201461939857P 2014-02-14 2014-02-14
US61/939,857 2014-02-14
US201462000162P 2014-05-19 2014-05-19
US62/000,162 2014-05-19
US201462025094P 2014-07-16 2014-07-16
US62/025,094 2014-07-16
US201462052227P 2014-09-18 2014-09-18
US62/052,227 2014-09-18
EP14306729 2014-10-29
EP14306729.6 2014-10-29
PCT/US2015/015633 WO2015123423A2 (en) 2014-02-14 2015-02-12 Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy

Publications (2)

Publication Number Publication Date
JP2017506626A JP2017506626A (ja) 2017-03-09
JP2017506626A5 true JP2017506626A5 (enExample) 2018-03-15

Family

ID=51870958

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016550471A Pending JP2017506626A (ja) 2014-02-14 2015-02-12 中程度用量スタチン療法により適切に管理されない高コレステロール血症を有する患者を処置するための方法

Country Status (10)

Country Link
US (2) US20150231236A1 (enExample)
EP (1) EP3104879A2 (enExample)
JP (1) JP2017506626A (enExample)
KR (1) KR20160115939A (enExample)
CN (1) CN106029096A (enExample)
AU (1) AU2015217118A1 (enExample)
CA (1) CA2939507A1 (enExample)
EA (1) EA201691320A1 (enExample)
MX (1) MX2016010504A (enExample)
WO (1) WO2015123423A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130064834A1 (en) 2008-12-15 2013-03-14 Regeneron Pharmaceuticals, Inc. Methods for treating hypercholesterolemia using antibodies to pcsk9
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CN110711248A (zh) * 2011-01-28 2020-01-21 赛诺菲生物技术公司 包含针对pcsk9的人抗体的药物组合物
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
ES2992345T3 (es) 2011-09-16 2024-12-11 Regeneron Pharma Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9)
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
US10058630B2 (en) 2012-10-22 2018-08-28 Concievalve, Llc Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
US20140257473A1 (en) * 2012-10-22 2014-09-11 Nalini Marie Rajamannan Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
US10111953B2 (en) 2013-05-30 2018-10-30 Regeneron Pharmaceuticals, Inc. Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9)
AU2014274844B2 (en) 2013-06-07 2019-11-28 Regeneron Pharmaceuticals, Inc. Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
EP3068803B1 (en) 2013-11-12 2021-01-20 Sanofi Biotechnology Dosing regimens for use with pcsk9 inhibitors
US20230374155A1 (en) * 2014-05-15 2023-11-23 Rani Therapeutics, Llc Pcsk9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
CN107072955B (zh) 2014-05-15 2021-06-18 拉尼医疗有限公司 包含多肽和/或蛋白质的固体块的药物组合物和该固体块的制备方法
US10689460B2 (en) * 2014-05-15 2020-06-23 Incube Labs, Llc PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US20170198059A1 (en) * 2014-07-14 2017-07-13 Amgen Inc. Crystalline antibody formulations
RU2735521C2 (ru) 2014-07-16 2020-11-03 Санофи Байотекнолоджи Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh)
US10772956B2 (en) 2015-08-18 2020-09-15 Regeneron Pharmaceuticals, Inc. Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab
CN108401419A (zh) 2015-09-08 2018-08-14 因库博实验室有限责任公司 使用可吞服药物递送装置递送到肠道内腔中的pcsk9抗体制剂
US10939164B2 (en) 2016-05-10 2021-03-02 Rovi Guides, Inc. Method and system for transferring an interactive feature to another device
EP3474780A4 (en) * 2016-06-27 2020-02-26 Concievalve LLC METHODS OF INHIBITING STENOSIS, OBSTRUCTING OR CALCIFYING A CARDIAC VALVE WITH STENT OR BIOPROSTHESIS
EP3609532A1 (en) 2017-04-13 2020-02-19 Cadila Healthcare Limited Novel peptide based pcsk9 vaccine
GB201720162D0 (en) 2017-12-04 2018-01-17 Univ Oxford Innovation Ltd Method
EP4470609A3 (en) 2019-01-18 2025-03-12 Astrazeneca AB Pcsk9 inhibitors and methods of use thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
CN110711248A (zh) * 2011-01-28 2020-01-21 赛诺菲生物技术公司 包含针对pcsk9的人抗体的药物组合物
ES2992345T3 (es) * 2011-09-16 2024-12-11 Regeneron Pharma Métodos para reducir los niveles de lipoproteína(a) mediante la administración de un inhibidor de la proproteína convertasa subtilisina kexina-9 (PCSK9)
US9255154B2 (en) * 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
AU2013266087A1 (en) * 2012-05-25 2014-12-04 Catabasis Pharmaceuticals, Inc. Methods of lowering proprotein convertase subtilisin/kexin type 9 (PCSK9)

Similar Documents

Publication Publication Date Title
JP2017506626A5 (enExample)
JP2017528427A5 (enExample)
JP7404471B2 (ja) 家族性高コレステロール血症を有する患者を処置するための方法
JP2016538248A5 (enExample)
JP2016538277A5 (enExample)
JP2022141868A (ja) 心血管リスクを低減させる方法
JP2016522211A5 (enExample)
JP7744190B2 (ja) リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
JP2017522316A5 (enExample)
JP2019514907A5 (enExample)
Bertrand et al. Inflammation and beyond: new directions and emerging drugs for treating atherosclerosis
JP2020002171A5 (enExample)
JP2022177142A5 (enExample)
JP2017509624A5 (enExample)
JP2016520616A5 (enExample)
IL277127B1 (en) Using pcsk9 tracking to reduce cardiovascular risk
JP2022000443A5 (enExample)
JP2017503820A5 (enExample)
RU2017104800A (ru) Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh)
RU2017104799A (ru) Способы лечения пациентов с высоким риском возникновения сердечно-сосудистых заболеваний, имеющих гиперхолестеринемию
JP2018523684A5 (enExample)
JP2016529255A5 (enExample)
JP2014516953A5 (enExample)
RU2017108173A (ru) Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1
JP7541810B2 (ja) Ａｎｇｐｔｌ３阻害剤と組み合わせてｐｃｓｋ９阻害剤を投与することにより高脂血症を有する患者を処置するための方法